Citations

Mayo Clinic

Showing 10 of 108599 citations.

What Is the Role of Organelle Membrane Contact Sites in Neurodegenerative Diseases?
Benarroch, Eduardo E.

Neurology | August 25, 2023 | Volume: 99 | Issue: 16 | Pages: 703-710

10.1212/wnl.0000000000201354 | PMID 36253131 Get It

Peripheral Nerve Stimulation of the Lesser Occipital and Greater Auricular Nerve for Post Herpetic Neuralgia in a Case of Ramsay Hunt Syndrome: Case Report
Johnson, Brooks , Covington, Stephen , Maita, Mostafa, Strand, Natalie , Johnson, Brooks W

Orthopedic Reviews | August 25, 2023 | Volume: 15 | Issue: No issue available | Pages: No page available

10.52965/001c.85149 | PMID 37641792 Get It

Background Post-herpetic neuralgia (PHN) is a painful condition that presents after herpes zoster reactivation in the peripheral and central nervous system. When medical treatment fails, options are limited, and patients may suffer with chronic pain indefinitely. Case Presentation We present the case of a gentleman with a 3-year history of PHN in the distribution of the right lesser occipital and greater auricular nerves that failed to respond to medical treatment. He underwent a trial of neuromodulation, and post-operative pain scores improved by 80%, and at 60 days post-operatively his average pain score was 0 out of 10. Conclusions PNS is an effective and safe option for the treatment of chronic pain, and we present a report of successful treatment of PHN in a particularly difficult anatomic distribution. PNS of the lesser occipital and greater auricular nerves is a novel treatment for PHN and shows promise as an effective, safe therapy when other treatment fails.
Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience
Coston, Tucker , Desai, Aakash , Babiker, Hani M. , Sonbol, Mohamad Bassam , Mahipal, Amit , McWilliams, Robert R. , Wee, Wen , Bekaii‐Saab, Tanios , Starr, Jason S. , Babiker, Hani , Chakrabarti, Sakti , Mahipal, Amit , McWilliams, Robert R , Ma, Wen Wee , Bekaii-Saab, Tanios S , A Stauffer, John , Starr, Jason S , Sonbol, Mohamad B , Desai, Aakash P , Chakrabarti, Sakti , Stauffer, John

JCO Precision Oncology | August 25, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.22.00706 | PMID 37625102 Get It

PURPOSE Pancreatic cancer (PC) carries a poor prognosis with high rates of unresectable/metastatic disease at diagnosis, recurrence after resection, and few systemic therapy options. Deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) PCs demonstrated uncharacteristically poor outcomes in KEYNOTE-158, evaluating pembrolizumab in MSI-H solid tumors. Our study aggregates the Mayo Clinic experience with dMMR/MSI-H PCs, characterizing the clinical, molecular, and treatment response patterns with a focus on response to immune checkpoint inhibitors (ICIs). METHODS Retrospective data were collected from the electronic medical record from December 2009 to February 2023. Patients were included if they had a pathologically confirmed pancreatic malignancy and had (1) deficient expression of mismatch repair (MMR) proteins by tumor immunohistochemistry, (2) pathogenic mutation of MMR genes on genomic sequencing, and/or (3) MSI-H by polymerase chain reaction. RESULTS Thirty-two patients were identified for inclusion, with all stages of disease represented. Sixteen of these patients underwent surgery or chemoradiotherapy. Of these patients, uncharacteristically favorable responses were seen, with a recurrence rate of only 19% (n = 3) despite a median follow-up of 25 months. In the palliative setting, excellent responses to ICI were seen, with overall response rate (ORR) of 75% (20% complete response). Median time to disease progression was not reached. Response rates to cytotoxic chemotherapy in the palliative setting were poor, with 30% ORR and median time to progression of 4 months. We observed a high rate of discrepancy between MMR and MSI testing methods, representing 19% of the entire cohort and 26% of evaluable cases. CONCLUSION Our data argue for the preferential use of ICI over cytotoxic chemotherapy in any patient with dMMR/MSI-H PC requiring systemic therapy, including in the metastatic and adjuvant/neoadjuvant settings.
Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39)
Blinder, Victoria , Deal, Allison M. , Ginos, Brenda, Jansen, Jennifer , Dueck, Amylou C. , Mazza, Gina L. , Henson, Sydney, Carr, Philip, Rogak, Lauren J. , Weiss, Anna , Rapperport, Anna, Jönsson, Mattias , Spears, Patricia A. , Cella, David , Gany, Francesca , Basch, Ethan , Dueck, A. C. , Blinder, Victoria S , Basch, Ethan , Mazza, Gina L , Deal, Allison , Jansen, Jennifer , Jonsson, Mattias , Schrag, Deborah

Journal of Clinical Oncology | August 25, 2023 | Volume: 41 | Issue: 29 | Pages: 4652-4663

10.1200/jco.22.02834 | PMID 37625107 Get It

PURPOSE Financial toxicity (FT) affects 20% of cancer survivors and is associated with poor clinical outcomes. No large-scale programs have been implemented to mitigate FT. We evaluated the effect of monthly FT screening as part of a larger patient-reported outcomes (PROs) digital monitoring intervention. METHODS PRO-TECT (AFT-39) is a cluster-randomized trial of patients undergoing systemic therapy for metastatic cancer. Practices were randomly assigned 1:1 to digital symptom monitoring (PRO practices) or usual care (control practices). Digital monitoring consisted of between-visit online or automated telephone patient surveys about symptoms, functioning, and FT (single-item screening question from Functional Assessment of Chronic Illness Therapy-COmprehensive Score for financial Toxicity) for up to 1 year, with automated alerts sent to practice nurses for concerning survey scores. Clinical team actions in response to alerts were not mandated. The primary outcome of this planned secondary analysis was development or worsening of financial difficulties, assessed via the European Organisation for Research and Treatment of Cancer QLQ-C30 financial difficulties measure, at any time compared with baseline. A randomly selected subset of patients and nurses were interviewed about their experiences with the intervention. RESULTS One thousand one hundred ninety-one patients were enrolled (593 PRO; 598 control) at 52 US community oncology practices. Overall, 30.2% of patients treated at practices that received the FT screening intervention developed, or experienced worsening of, financial difficulties, compared with 39.0% treated at control practices ( P = .004). Patients and nurses interviewed stated that FT screening identified patients for financial counseling who otherwise would be reluctant to seek, or unaware of the availability of, assistance. CONCLUSION In this report of a secondary outcome from a randomized clinical trial, FT screening as part of routine digital patient monitoring with PROs reduced the development, or worsening, of financial difficulties among patients undergoing systemic cancer therapy.
Impact of Intra-Articular Corticosteroid Injection on Glycemic Control: A Population-Based Cohort Study
Sytsma, Terin T. , Greenlund, Laura S. , McCoy, Rozalina G. , McCoy, Rozalina Grubina , Fischer, Karen M.

Clinical Diabetes | August 25, 2023 | Volume: 42 | Issue: 1 | Pages: 96-103

10.2337/cd22-0124 | PMID 38230338 Get It

This retrospective cohort study investigated the longer-term hyperglycemic effects of intra-articular corticosteroid (IACS) administration by evaluating changes in A1C after large joint IACS injection. Among 1,169 patients (mean age 66.1 ± 12.2 years, 52.8% female), 184 (15.7%) experienced a greater-than-expected rise in A1C (actual A1C ≥0.5% above predicted) after IACS. Greater-than-expected rise in A1C was associated solely with baseline A1C (odds ratio [OR] 1.84, 95% CI 1.08–3.13 for baseline A1C of 7.0–8.0% compared with <7.0% and OR 4.79, 95% CI 2.83–8.14 for baseline A1C >8.0% compared with <7.0%). Although most patients do not experience an increase in A1C after IACS, clinicians should counsel patients with suboptimally controlled diabetes about risks of further hyperglycemia after IACS administration.
Learning to collaborate with medical interpreters in health professions education: A systematic review of training programs
Fukui, Natsu , Yeow, Mei-Ean , Farfour, Hannah , Prokop, Larry J. , Barwise, Amelia , Partain, Daniel K , Yeow, Mei-Ean , Farfour, Hannah N , Prokop, Larry , Barwise, Amelia K , Partain, Daniel K.

Medical Teacher | August 25, 2023 | Volume: 46 | Issue: 2 | Pages: 258-272

10.1080/0142159x.2023.2249211 | PMID 37625438 Get It

What Is the Mechanism of Therapeutic and Adverse Effects of Gabapentinoids?
Benarroch, Eduardo E.

Neurology | August 25, 2023 | Volume: 96 | Issue: 7 | Pages: 318-321

10.1212/wnl.0000000000011424 | PMID 33589478 Get It

Word Embedding Neural Networks to Advance Knee Osteoarthritis Research
Amirian, Soheyla , Ghazaleh, Husam , Assefi, Mehdi, Plate, Johannes F. , Kremers, Hilal Maradit , Arabnia, Hamid Reza , Tafti, Ahmad P

2022 International Conference on Computational Science and Computational Intelligence (CSCI) | August 25, 2023 | Volume: No volume available | Issue: No issue available | Pages: 289-292

10.1109/csci58124.2022.00055 Get It

Loneliness, Immunological Recovery Patterns, and Health-Related Quality of Life (HRQOL) Outcomes in Patients Receiving Hematopoietic Stem Cell Transplantation
Ames, Steven C. , Ames, Gretchen E. , White, Launia J. , Foran, James M. , Lange, Lori , Heckman, Michael G. , Roy, Vivek

No container title available | August 25, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3276417/v1 Get It

Abstract Purpose Loneliness may compromise health-related quality of life (HRQOL) outcomes and the immunological impacts of loneliness via neuroendocrinological mechanisms likely have consequences for patients who have undergone a hematopoietic stem cell transplantation (HSCT). Research Approach and Measures: Loneliness (pre-transplant), immunological recovery (Day 30, Day 100, 1-year post-transplant), and HRQOL (Day 100, 1 year) were measured in a sample of 205 patients completing a HSCT (127 autologous, 78 allogenic). Results Greater levels of pre-transplant loneliness predicted poorer HRQOL at Day 100 and 1-year follow-up. Loneliness also was associated with higher absolute neutrophil to absolute lymphocyte (ANC/ALC) ratios in the entire sample at Day 30, which in turn predicted Day 100 HRQOL. Conclusions Findings demonstrate that pretransplant loneliness predicts HRQOL outcomes and inflammatory immunological recovery patterns in HSCT patients. The balance of innate neutrophils to adaptive lymphocytes at Day 30 present a distinct profile in lonely individuals, with this immunity recovery profile predicting reduced HRQOL 100 days after the transplant. Addressing perceptions of loneliness before HSCT may be an important factor in improving immunological recovery and HRQOL outcomes.
Circulating Growth Differentiation Factors 11 and 8, Their Antagonists Follistatin and Follistatin-Like-3, and Risk of Heart Failure in Elders
Patel, Sheena, Ganz, Peter , Bhasin, Shalender , Lee, Se‐Jin , Shah, Sanjiv J. , Cummings, Steven R. , Ganz, Peter , Newman, Anne B. , Bhasin, Shalinder , Shah, Sanjiv J , Kizer, Jorge R. , Cawthon, Peggy M. , LeBrasseur, Nathan K. , Psaty, Bruce M. , Tracy, Russell P.

The Journals of Gerontology: Series A | August 25, 2023 | Volume: 79 | Issue: 1 | Pages: No page available

10.1093/gerona/glad206 | PMID 37624693 Get It

Abstract Background Heterochronic parabiosis has identified growth differentiation factor (GDF)-11 as a potential means of cardiac rejuvenation, but findings have been inconsistent. A major barrier has been lack of assay specificity for GDF-11 and its homolog GDF-8. Methods We tested the hypothesis that GDF-11 and GDF-8, and their major antagonists follistatin and follistatin-like (FSTL)-3, are associated with incident heart failure (HF) and its subtypes in elders. Based on validation experiments, we used liquid chromatography–tandem mass spectrometry to measure total serum GDF-11 and GDF-8, along with follistatin and FSTL-3 by immunoassay, in 2 longitudinal cohorts of older adults. Results In 2 599 participants (age 75.2 ± 4.3) followed for 10.8 ± 5.6 years, 721 HF events occurred. After adjustment, neither GDF-11 (HR per doubling: 0.93 [0.67, 1.30]) nor GDF-8 (HR: 1.02 per doubling [0.83, 1.27]) was associated with incident HF or its subtypes. Positive associations with HF were detected for follistatin (HR: 1.15 [1.00, 1.32]) and FLST-3 (HR: 1.38 [1.03, 1.85]), and with HF with preserved ejection fraction for FSTL-3 (HR: 1.77 [1.03, 3.02]). (All HRs per doubling of biomarker.) FSTL-3 associations with HF appeared stronger at higher follistatin levels and vice versa, and also for men, Blacks, and lower kidney function. Conclusions Among older adults, serum follistatin and FSTL-3, but not GDF-11 or GDF-8, were associated with incident HF. These findings do not support the concept that low serum levels of total GDF-11 or GDF-8 contribute to HF late in life, but do implicate transforming growth factor-β superfamily pathways as potential therapeutic targets.